top of page
What Are HER2-Low and HER2-Ultralow Breast Cancer? Testing and Treatment — 2026 Guideline Update

What Are HER2-Low and HER2-Ultralow Breast Cancer? Testing and Treatment — 2026 Guideline Update

ป้าหมอนุช
13 hours ago
6 min read

HER2-low and HER2-ultralow describe breast cancers that are "HER2-negative" by the traditional definition but still carry low levels of HER2 protein on the cell surface. They account for more than half of HER2-negative breast cancers. Their importance is that when the disease is metastatic, patients can receive the antibody–drug conjugate trastuzumab deruxtecan (T-DXd), which controls the disease longer than standard chemotherapy. At Namarak Hospital, our team uses detailed HER2 results to plan treatment according to the latest 2026 NCCN and ESMO guidelines.

This article explains what HER2-low and HER2-ultralow are, how they differ from HER2-positive disease, when to test, and how they affect treatment at each stage.

What are HER2-low and HER2-ultralow?

Pathologists test HER2 by immunohistochemistry (IHC), scoring the intensity and proportion of stained cells, together with a gene test (ISH) in equivocal cases.

  • HER2-positive — IHC 3+, or IHC 2+ with gene amplification on ISH; treated with full HER2-targeted therapy. See HER2-positive breast cancer

  • HER2-low — IHC 1+, or IHC 2+ with negative ISH

  • HER2-ultralow — IHC 0 but with faint membrane staining in no more than 10% of cells (sometimes written as IHC 0+)

  • HER2-null (HER2-0) — no membrane staining at all

HER2-low is not a new biological subtype; it is a "treatment signpost" in metastatic disease. Most cases are hormone receptor–positive (HR+), and a minority are triple-negative (TNBC).

Accuracy of low-level HER2 testing

Distinguishing IHC 0, 0+ and 1+ requires expertise, because the difference lies in very faint staining. The 2026 international consensus (Rakha et al., Modern Pathology) recommends validated reagents and staining methods, quality controls, dedicated pathologist training, and reports that clearly separate HER2-0, HER2-ultralow and HER2-low.

  • HER2 levels can change — the original tumor and a metastatic site may give different results; if any sample is HER2-low, the patient is considered eligible for treatment

  • Ask about re-testing when metastasis is first diagnosed, or when a previous result was IHC 0 and a change from endocrine therapy to another drug class is being considered

  • Tissue handling from the operating room to the laboratory affects HER2 accuracy, so it must follow standards

Early stage (stage I–III): still treated according to hormone status

In early-stage disease, a HER2-low or HER2-ultralow result does not change the treatment plan. Doctors treat mainly according to hormone receptor status.

  • Hormone receptor–positive (HR+/HER2-low): surgery, radiation, endocrine therapy, and chemotherapy or CDK4/6 inhibitors according to risk, just as for HR+/HER2− disease. See HR+/HER2− breast cancer

  • Triple-negative (HER2-low): treated as TNBC, with chemotherapy plus immunotherapy before surgery for stage II–III. See What is TNBC?

  • No HER2-targeted drug is currently approved for HER2-low disease in the early stage; T-DXd in this setting remains under research

Metastatic disease: T-DXd changes the treatment sequence

In metastatic disease, HER2-low and HER2-ultralow results are very important, because trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate (ADC), can bind HER2 even at low levels and release chemotherapy into the cancer cell and neighboring cells (bystander effect).

Hormone receptor–positive with HER2-low or HER2-ultralow

  • First line remains endocrine therapy with targeted drugs, such as a CDK4/6 inhibitor, as for HR+/HER2− disease

  • After endocrine therapy stops working: T-DXd is an option before chemotherapy, based on DESTINY-Breast06, which extended median progression-free survival to 13.2 months versus 8.1 months with chemotherapy (HR 0.64), with response rates of 56.5% versus 32.2%; the FDA approved it in January 2025 for both HER2-low and HER2-ultralow after at least 1 line of endocrine therapy

  • Recommended timing: NCCN (Version 4.2026) after at least 1 line of endocrine therapy; ESMO 2026 after at least 2 lines, or earlier with rapid endocrine resistance

  • After chemotherapy: T-DXd still provides clear benefit, based on DESTINY-Breast04, which improved both progression-free and overall survival compared with physician's choice of chemotherapy

  • Data for HER2-ultralow come from fewer patients; results point in the same direction but were not statistically significant in this subgroup

Triple-negative with HER2-low

  • First line follows TNBC guidelines, such as chemotherapy with immunotherapy for PD-L1-positive disease, or a TROP2-directed ADC

  • T-DXd is an option in a later line after at least 1 line of chemotherapy (DESTINY-Breast04 included a small number of these patients); ESMO 2026 states it may be considered in later lines

  • There is no approved indication for HER2-ultralow TNBC

Brain metastases

ESMO 2026 recommends T-DXd for HER2-low disease with active brain metastases and states it may be considered for leptomeningeal disease, although this use is not specifically approved by the FDA or EMA. It is usually combined with local treatment such as stereotactic radiosurgery.

Sequencing ADCs

Several ADCs are now available for HER2-negative breast cancer: T-DXd, datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan. They have different targets but share the same class of chemotherapy payload (topoisomerase I inhibitor), so a second ADC after the first often works less well. The best sequence has not been established; the doctor will choose according to HER2 level, previous treatments and side effects.

T-DXd side effects you should know

  • Drug-induced lung inflammation (ILD/pneumonitis) — the most important side effect, in about 1 in 10 patients, mostly mild when detected early; lung CT scans are scheduled periodically, and cough, shortness of breath or fever should be reported right away

  • Nausea and vomiting — common early on, prevented with a combination of anti-nausea drugs

  • Fatigue, hair thinning, low blood counts — monitored with blood tests before each cycle

  • Heart function — echocardiogram before starting and periodically

Important note: the registered indications of T-DXd and other ADCs in Thailand may differ from the US or Europe, and reimbursement varies. Our team will explain the options that are actually available and the estimated costs.

Summary of HER2-low / HER2-ultralow by situation

  • Early stage I–III: treated according to hormone status (HR+ or TNBC); a HER2-low result does not change the plan

  • Metastatic HR+, first line: endocrine therapy + CDK4/6 inhibitor

  • Metastatic HR+, after endocrine therapy stops working: T-DXd (HER2-low and HER2-ultralow), before or after chemotherapy

  • Metastatic TNBC + HER2-low: treat as TNBC first, then consider T-DXd in a later line

  • Any metastatic case: ask for HER2 re-testing on a new biopsy if the previous result was HER2-0

Frequently asked questions (FAQ)

Is HER2-low positive or negative?

HER2-low belongs to the HER2-negative group, because it does not benefit from traditional HER2-targeted drugs such as trastuzumab, but it carries enough HER2 for T-DXd to work in metastatic disease.

How is HER2-ultralow different from HER2-low?

HER2-ultralow shows less HER2 staining than HER2-low: IHC 0 but with faint membrane staining in no more than 10% of cells. The FDA has approved T-DXd for this group in hormone receptor–positive metastatic disease after endocrine therapy stops working.

Does a HER2-low result change early-stage treatment?

No. In early-stage disease, treatment is based mainly on hormone receptor status. HER2-low becomes important when the disease is metastatic.

My previous result was HER2-0. Should it be re-tested?

It is worth considering, especially in metastatic disease, because HER2 levels can change over time and between sites. If a new sample is HER2-low or HER2-ultralow, additional treatment options may be available.

How is T-DXd better than standard chemotherapy?

In DESTINY-Breast04 and DESTINY-Breast06, T-DXd controlled the disease longer and had higher response rates than physician's choice of chemotherapy, but it has specific side effects such as drug-induced pneumonitis that require close monitoring.

How long can T-DXd be given?

It is given every 3 weeks until the disease progresses or side effects require stopping. Pneumonitis of grade 2 or higher requires permanent discontinuation.

Is this drug available in Thailand?

T-DXd is available in Thailand, but registered indications and reimbursement may differ from other countries. Our team will help check insurance coverage and suitable options.

About Namarak Hospital

Namarak Hospital is a specialized breast hospital in Bangkok, where breast surgeons, medical oncologists, radiologists and pathologists plan treatment together as a multidisciplinary team according to the latest international guidelines. To discuss HER2 results or request a second opinion, see Breast Cancer Treatment, Second Opinion, or contact us on LINE, tel. +66 2 059 0245.

Related treatment guides by cancer type

References

  • NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 4.2026

  • de Azambuja E, et al. Metastatic breast cancer: ESMO Clinical Practice Guideline. Ann Oncol 2026

  • Rakha EA, et al. International consensus on HER2-low and HER2-ultralow reporting. Mod Pathol 2026

  • Bardia A, et al. Trastuzumab deruxtecan after endocrine therapy in HER2-low and HER2-ultralow breast cancer (DESTINY-Breast06). N Engl J Med 2024 · US FDA approval, 27 Jan 2025

  • Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer (DESTINY-Breast04). N Engl J Med 2022

Medically reviewed by: Namarak Hospital medical team · Guidelines checked: 16 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.

Comments


Link to the Namarak Hospital medical team profiles
bottom of page